Publikationen

Irmscher S, Döring N, Halder LD, Jo EAH, Kopka I, Dunker C, Jacobsen ID, Luo S, Slevogt H, Lorkowski S, Beyersdorf N, Zipfel PF, Skerka C (2018) Kallikrein cleaves C3 and activates complement. J Innate Immun 10(2), 94-105.
Luo S, Dasari P, Reiher N, Hartmann A, Jacksch S, Wende E, Barz D, Niemiec MJ, Jacobsen I, Beyersdorf N, Hünig T, Klos A, Skerka C, Zipfel PF (2018) The secreted Candida albicans protein Pra1 disrupts host defense by broadly targeting and blocking complement C3 and C3 activation fragments. Mol Immunol 93, 266-277.
Meinel C, Spartà G, Dahse HM, Hörhold F, König R, Westermann M, Cseresnyés Z, Coldewey SM, Figge MT, Hammerschmidt S, Skerka C, Zipfel PF (2018) Streptococcus pneumoniae from patients with hemolytic uremic syndrome binds human plasminogen via the surface protein PspC and uses plasmin to damage human endothelial cells. J Infect Dis 217(3), 358-370.
Michelfelder S, Fischer F, Wäldin A, Hörle K, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K (2018) The MFHR1 fusion protein is a novel synthetic multitarget complement inhibitor with therapeutic potential. J Am Soc Nephrol 29(4), 1141-1153.
Pujol-Lereis LM, Liebisch G, Schick T, Lin Y, Grassmann F, Uchida K, Zipfel PF, Fauser S, Skerka C, Weber BHF (2018) Evaluation of serum sphingolipids and the influence of genetic risk factors in age-related macular degeneration. PLOS One 13(8), e0200739.
Reiss T, Rosa TFA, Blaesius K, Bobbert RP, Zipfel PF, Skerka C, Pradel G (2018) FHR-1 binding impairs factor H-mediated complement evasion by the malaria parasite Plasmodium falciparum. J Immunol 201(12), 3497-3502.
Rudnick RB, Chen Q, Stea ED, Hartmann A, Papac-Milicevic N, Person F, Wiesener M, Binder CJ, Wiech T, Skerka C, Zipfel PF (2018) FHR5 binds to laminins, uses separate C3b and surface-binding sites, and activates complement on malondialdehyde-acetaldehyde surfaces. J Immunol 200(7), 2280-2290.
Spartà G, Gaspert A, Neuhaus TJ, Weitz M, Mohebbi N, Odermatt U, Zipfel PF, Bergmann C, Laube GF (2018) Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: Change in treatment modality? A report on a case series. Clin Kidney J 11(4), 479-490.
Zipfel PF, Luo S, Dasari P, Reiher N, Jacobsen I, Beyersdorf N, Klos A, Serka C (2018) Reply to kang and brooks: Comment on the interpretation of binding of Pra1, the fungal immune evasion protein from Candida albicans to the human C3 and on the conformational changes of C3 upon activation: Kang and brooks optimization of biolayer-interfero. Mol Immunol 101, 638-639.
Becker T, Pasteels J, Weigel C, Dahse HM, Voigt K, Boland W (2017) A tale of four kingdoms - isoxazolin-5-one- and 3-nitropropanoic acid-derived natural products. Natural Product Reports 34(4), 343-360.